Conference detail

Charlotte Harrison

In the past year, the detection and characterization of fluid-based biomarkers in oncology witnessed an unprecedented level of progress, investment and industry partnership announcements. However, as the liquid assay landscape matures and the level of sensitivity and selectivity achieved by assays creates excitement for precision drug development, there remains a number of unique hurdles to translate rapid technical advancements seen towards the development of more effective and accessible precision oncology treatments.

That's why the 6th Liquid Biopsy for Precision Oncology Summit will take place this February in San Diego, giving you the first opportunity in over a year to network, collaborate with and learn directly from your peers at a face-to-face forum.

As industry's most comprehensive liquid biopsy meeting, unite with 300+ key decision makers including Pfizer, AstraZeneca, Mirati Therapeutics, Kura Oncology, GSK, BloodPAC, International Society of Liquid Biopsy, Guardant Health, Natera and many more to address the key scientific, technical, regulatory, commercial and testing access challenges associated with progressing precision oncology pipelines harnessing liquid biopsy technology.

With the rise of early detection and IO assays, expansion of MRD monitoring, CDx reimbursement announcements and a wealth of therapeutically relevant biomarkers being identified, here lies your prime opportunity to meet diverse stakeholders, in person, and discover the most cutting-edge scientific data to strengthen your pipeline and capitalize on the vast amount of progress the field is witnessing.